PCI Biotech Holding Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 15
Employees
  • Stock Symbol
  • PCIB
Stock Symbol
  • Share Price
  • $3.20
  • (As of Friday Closing)

PCI Biotech Holding General Information

Description

PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Stock Exchange
OSL
Primary Office
  • Ullernchauséen 64
  • 0379 Oslo
  • Norway
+47 67 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PCI Biotech Holding Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.20 $3.19 $2.12 - $9.18 $119M 37.3M 119K -$0.29

PCI Biotech Holding Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 89,909 99,734 292,900 109,669
Revenue 0 0 0
EBITDA (8,503) (7,554) (10,187) (4,347)
Net Income (10,913) (7,634) (10,081) (4,271)
Total Assets 21,784 24,497 31,978 40,983
Total Debt 59 79 136 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PCI Biotech Holding Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PCI Biotech Holding‘s full profile, request access.

Request a free trial

PCI Biotech Holding Executive Team (6)

Name Title Board Seat Contact Info
Per Walday Ph.D Chief Executive Officer
Ronny Skuggedal Chief Financial Officer, Finance
Anders Høgset Ph.D Chief Scientific Officer & Research Director
Ludovic Robin Chief Business Officer
Amir Snapir Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

PCI Biotech Holding Board Members (9)

Name Representing Role Since
Hans Bøhn MD PCI Biotech Holding Chairman of the Board 000 0000
Hilde Steineger Ph.D Self Board Member 000 0000
Kjetil Taskén Ph.D Self Board Member 000 0000
Lars Viksmoen MD Self Board Member 000 0000
You’re viewing 4 of 9 board members. Get the full list »

PCI Biotech Holding Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PCI Biotech Holding Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PCI Biotech Holding‘s full profile, request access.

Request a free trial